Phase 2 Liver Cancer Trial, Recruiting NCT05692024 Sponsor: Massachusetts General Hospital Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT05692024
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with stage I, II, or III colon or rectal cancer (confirmed by a laboratory test on tissue) and have finished standard treatment — including surgery, chemotherapy, and/or radiation — at least 2 months ago.
  • People aged 18 years or older.
  • People who are able and willing to follow the study procedures and instructions throughout the trial.
  • People who are willing to sign a written consent form showing they understand and agree to take part.
  • People who are able to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) for the duration of the study — this applies to both women who could become pregnant and to men.

Who may not be able to join:

  • People who are currently taking part in another clinical trial involving an investigational treatment.
  • People who are currently receiving any other cancer treatment, such as chemotherapy, targeted therapy, immunotherapy, or any other anti-cancer agent.
  • People who have regularly drunk more than 2 cups of coffee (8 oz per cup) per day, on at least 3 days per week, during the past month.
  • People who have used coffee supplements (such as green coffee extract) within the past month.
  • People who have been diagnosed with certain health conditions that may be made worse by coffee, including heart rhythm problems, insomnia, tremors, tics, generalised anxiety disorder, bipolar disorder, panic attacks, Tourette's syndrome, epilepsy, or overactive bladder.
  • People who have had a bad reaction to coffee in the past, or who cannot tolerate drinking coffee.
  • People who are unable or unwilling to swallow capsules.
  • People who have a history of problems absorbing food or medications, uncontrolled vomiting or diarrhoea, or any condition that could interfere with how oral medications are absorbed.
  • People with any serious uncontrolled illness — such as an active infection, heart failure, unstable chest pain, or significant mental health or social circumstances — that the trial doctor believes could affect safety, participation, or the reliability of results.
  • People who are pregnant or breastfeeding, as the effects of coffee on unborn babies and nursing infants are not yet known.
  • People who currently have another cancer for which they are receiving active treatment at the same time.
  • People who have a known positive test result for HIV, hepatitis C, or active or chronic hepatitis B.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Aparna R Parikh, MD, MS, Massachusetts General Hospital

Phone: (617) 643-3364

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
21 March 2024
Est. completion
31 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in hepatic fat fraction.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov